VLDLR and neoplasm: By inhibiting PCSK9 production at the hepatic level, inclisiran may enhance immune surveillance by increasing low-density lipoprotein receptor (LDLR) expression on immune cells, thereby promoting lipid homeostasis in the tumor microenvironment [180].